Aller au contenu principal
Accès ouvert déclaré 2020 article

Chemoradiation in Stage IIIB Cancer of the Uterine Cervix: A Review of the Zimbabwean Experience

5Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : Zimbabwe, us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

PURPOSE Cervical cancer remains the leading cause of cancer morbidity and mortality among Zimbabwean women. Many patients present with stage IIIB disease. Although definitive concurrent chemoradiation (CCRT) is the standard of care, there is a paucity of data on the effect(s) of this intervention in resource-constrained and high HIV-prevalence settings. We investigated the differences in CCRT initiation practices, tolerability, and outcomes in this group. PATIENTS AND METHODS We performed a retrospective analysis of data from hospital records for patients with stage IIIB disease who were treated over a 2-year period at Parirenyatwa Group of Hospitals. Outcome measures were documented treatment-related adverse events and early clinical tumor response. RESULTS One hundred twenty-eight (37%) of 346 patients received CCRT, and 65 (51%) of 128 patients were infected with HIV. CCRT was prescribed mostly in patients with less extensive disease—not involving lower third vaginal walls, minimal pelvic sidewall involvement ( P = .002), and higher CD4+ count ( P = .02). Eighteen percent of recorded adverse events were high grade (≥ 3). One patient did not complete treatment, and 68.5% achieved complete clinical tumor response at 3 months post-CCRT. A higher proportion of complete clinical tumor response was noted in those patients who were young, HIV uninfected, had less extensive disease, CD4+ of 500 cells/mm3 or greater, received four or more cycles of chemotherapy, received brachytherapy, and had no treatment breaks. CONCLUSION The study revealed that the use of CCRT to treat stage IIIB cervical cancer is low in Zimbabwe. Although several factors contribute, low CCRT uptake is mostly attributed to financial barriers. Well-selected patients tolerate the treatment and have good early clinical tumor response as expected. The role of CCRT for this patient group (and methods to make it available in resource-limited settings) must be further evaluated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Chemoradiation in Stage IIIB Cancer of the Uterine Cervix: A Review of the Zimbabwean Experience
Date Crossref
01/11/2020
Éditeur
American Society of Clinical Oncology (ASCO)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • University of Zimbabwe Department of Oncology Harare, Zimbabwe (code pays fourni par la source)
    Université ou école supérieure
  • University at Buffalo Center for Integrated Global Biomedical Sciences pays non établi dans la notice
    Université ou école supérieure
  • School of Pharmacy and Pharmaceutical Sciences Harare, Zimbabwe (pays nommé en fin d’affiliation)
    Université ou école supérieure

Department of Oncology — University of Zimbabwe (Harare, Zimbabwe), Center for Integrated Global Biomedical Sciences — University at Buffalo et School of Pharmacy and Pharmaceutical Sciences (Harare, Zimbabwe). Pays d’affiliation : Zimbabwe.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cervical Cancer and HPV ResearchEndometrial and Cervical Cancer TreatmentsAdvances in Oncology and Radiotherapy

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.